Fibromyalgia: An Overview

American Journal of Medicine

Volumn 122, Issue 12 SUPPL., 2009, Pages

  Clauw, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Central pain syndromes; Diagnosis; Fibromyalgia; Hyperalgesia; Musculoskeletal pain; Neuroimaging

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMITRIPTYLINE; BENZODIAZEPINE; CITALOPRAM; CORTICOSTEROID; CYCLOBENZAPRINE; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; GABAPENTIN; GROWTH HORMONE; GUAIFENESIN; HYPNOTIC AGENT; MELATONIN; MILNACIPRAN; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PRAMIPEXOLE; PRASTERONE; PREGABALIN; S ADENOSYLMETHIONINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ACUPUNCTURE; ALLODYNIA; AMINO ACID BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; BALNEOTHERAPY; BRAIN BLOOD FLOW; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM; CHIROPRACTIC; CHRONIC PAIN; CLINICAL EVALUATION; CLINICAL EXAMINATION; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; ELECTROSTIMULATION THERAPY; EMOTIONAL STRESS; ENVIRONMENTAL FACTOR; FATIGUE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC POLYMORPHISM; HEADACHE; HEART RATE VARIABILITY; HEREDITY; HUMAN; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KINESIOTHERAPY; LOW DRUG DOSE; MANIPULATIVE MEDICINE; MASSAGE; MENTAL DISEASE; MIGRAINE; MOLECULAR MECHANICS; MUSCULOSKELETAL PAIN; NEUROIMAGING; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NORADRENERGIC SYSTEM; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; POSTHERPETIC NEURALGIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOPHYSIOLOGY; RECEPTOR AFFINITY; RHEUMATOID ARTHRITIS; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; STIMULUS RESPONSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TENSION HEADACHE; TREATMENT OUTCOME; ULTRASOUND;

ANALGESICS; ANTIDEPRESSIVE AGENTS; BRAIN; FIBROMYALGIA; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROSECRETORY SYSTEMS; PAIN; SLEEP DISORDERS; STRESS, PHYSIOLOGICAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 70749145982     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.09.006     Document Type: Article

References (143)

1. Bennett R.M., Jones J., Turk D.C., Russell I.J., and Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 8 (2007) 27
2. Hudson J.I., Hudson M.S., Pliner L.F., Goldenberg D.L., and Pope Jr. H.G. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 142 (1985) 441-446
3. Arnold L.M., Hudson J.I., Hess E.V., et al. Family study of fibromyalgia. Arthritis Rheum 50 (2004) 944-952
4. Drossman D.A. Sexual and physical abuse and gastrointestinal illness. Scand J Gastroenterol Suppl 208 (1995) 90-96
5. Aaron L.A., Bradley L.A., Alarcon G.S., et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 39 (1996) 436-445
6. Maixner W., Fillingim R., Booker D., and Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 63 (1995) 341-351
7. Naliboff B.D., Derbyshire S.W., Munakata J., et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 63 (2001) 365-375
8. Giesecke T., Gracely R.H., Grant M.A., et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 50 (2004) 613-623
9. Giesecke J., Reed B.D., Haefner H.K., Giesecke T., Clauw D.J., and Gracely R.H. Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. Obstet Gynecol 104 (2004) 126-133
10. Moshiree B., Price D.D., Robinson M.E., Gaible R., and Verne G.N. Thermal and visceral hypersensitivity in irritable bowel syndrome patients with and without fibromyalgia. Clin J Pain 23 (2007) 323-330
11. Smythe H.A., and Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis 28 (1977) 928-931
12. Moldofsky H., Scarisbrick P., England R., and Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 37 (1975) 341-351
13. Yunus M., Masi A.T., Calabro J.J., Miller K.A., and Feigenbaum S.L. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11 (1981) 151-171
14. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 33 (1990) 160-172
15. Yunus M.B. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 19 (1992) 846-850
16. Clauw D.J., and Chrousos G.P. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 4 (1997) 134-153
17. Wessely S., Nimnuan C., and Sharpe M. Functional somatic syndromes: one or many?. Lancet 354 (1999) 936-939
18. Barsky A.J., and Borus J.F. Functional somatic syndromes. Ann Intern Med 130 (1999) 910-921
19. Fukuda K., Nisenbaum R., Stewart G., et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA 280 (1998) 981-988
20. Hudson J.I., Goldenberg D.L., Pope Jr. H.G., Keck Jr. P.E., and Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92 (1993) 363-367
21. Clauw D.J. Fibromyalgia: update on mechanisms and management. J Clin Rheumatol 13 (2007) 102-109
22. Woolf C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140 (2004) 441-451
23. Yunus M.B. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 37 (2008) 339-352
24. Buskila D., Neumann L., Hazanov I., and Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 26 (1996) 605-611
25. Kato K., Sullivan P.F., Evengard B., and Pedersen N.L. Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med 166 (2006) 1649-1654
26. Kato K., Sullivan P.F., Evengard B., and Pedersen N.L. Importance of genetic influences on chronic widespread pain. Arthritis Rheum 54 (2006) 1682-1686
27. Bondy B., Spaeth M., Offenbaecher M., et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 6 (1999) 433-439
28. Offenbaecher M., Bondy B., de Jonge S., et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42 (1999) 2482-2488
29. Buskila D., Cohen H., Neumann L., and Ebstein R.P. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 9 (2004) 730-731
30. Buskila D. Genetics of chronic pain states. Best Pract Res Clin Rheumatol 21 (2007) 535-547
31. Sapolsky R.M. Why stress is bad for your brain. Science 273 (1996) 749-750
32. Chrousos G.P., and Gold P.W. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 267 (1992) 1244-1252
33. Pillow D.R., Zautra A.J., and Sandler I. Major life events and minor stressors: identifying mediational links in the stress process. J Pers Soc Psychol 70 (1996) 381-394
34. Clauw D.J., Engel Jr. C.C., Aronowitz R., et al. Unexplained symptoms after terrorism and war: an expert consensus statement. J Occup Environ Med 45 (2003) 1040-1048
35. Heim C., Newport D.J., Bonsall R., Miller A.H., and Nemeroff C.B. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry 158 (2001) 575-581
36. McLean S.A., and Clauw D.J. Predicting chronic symptoms after an acute "stressor"-lessons learned from 3 medical conditions. Med Hypotheses 63 (2004) 653-658
37. Aaron L.A., Bradley L.A., Alarcon G.S., et al. Perceived physical and emotional trauma as precipitating events in fibromyalgia: associations with health care seeking and disability status but not pain severity [see comments]. Arthritis Rheum 40 (1997) 453-460
38. Alexander R.W., Bradley L.A., Alarcon G.S., et al. Sexual and physical abuse in women with fibromyalgia: association with outpatient health care utilization and pain medication usage. Arthritis Care Res 11 (1998) 102-115
39. Boisset-Pioro M.H., Esdaile J.M., and Fitzcharles M.A. Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum 38 (1995) 235-241
40. Arguelles L.M., Afari N., Buchwald D.S., Clauw D.J., Furner S., and Goldberg J. A twin study of posttraumatic stress disorder symptoms and chronic widespread pain. Pain 124 (2006) 150-157
41. Glass J.M., Lyden A., Petzke F., and Clauw D. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 57 (2004) 391-398
42. McBeth J., Silman A.J., Gupta A., et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum 56 (2007) 360-371
43. Arnson Y., Amital D., Fostick L., et al. Physical activity protects male patients with post-traumatic stress disorder from developing severe fibromyalgia. Clin Exp Rheumatol 25 (2007) 529-533
44. Crofford L.J., Pillemer S.R., Kalogeras K.T., et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37 (1994) 1583-1592
45. Demitrack M.A., and Crofford L.J. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 840 (1998) 684-697
46. Qiao Z.G., Vaeroy H., and Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol 18 (1991) 1383-1389
47. Adler G.K., Kinsley B.T., Hurwitz S., Mossey C.J., and Goldenberg D.L. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 106 (1999) 534-543
48. Martinez-Lavin M., Hermosillo A.G., Rosas M., and Soto M.E. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 41 (1998) 1966-1971
49. Cohen H., Neumann L., Shore M., Amir M., Cassuto Y., and Buskila D. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Sem Arthritis Rheum 29 (2000) 217-227
50. Catley D., Kaell A.T., Kirschbaum C., and Stone A.A. A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res 13 (2000) 51-61
51. McLean S.A., Williams D.A., Stein P.K., et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 31 (2006) 2776-2782
52. Cohen H., Buskila D., Neumann L., and Ebstein R.P. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 46 (2002) 845-847
53. Bou-Holaigah I., Calkins H., Flynn J.A., et al. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 15 (1997) 239-246
54. Naschitz J.E., Rosner I., Rozenbaum M., et al. The capnography head-up tilt test for evaluation of chronic fatigue syndrome. Semin Arthritis Rheum 30 (2000) 79-86
55. McBeth J., and Jones K. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 21 (2007) 403-425
56. Wolfe F., Ross K., Anderson J., and Russell I.J. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 22 (1995) 151-156
57. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56 (1997) 268-271
58. Gracely R.H., Grant M.A., and Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 17 (2003) 593-609
59. Jensen K., Andersen H.O., Olesen J., and Lindblom U. Pressure-pain threshold in human temporal region: evaluation of a new pressure algometer. Pain 25 (1986) 313-323
60. Petzke F., Gracely R.H., Park K.M., Ambrose K., and Clauw D.J. What do tender points measure?. nfluence of distress on 4 measures of tenderness. J Rheumatol 30 (2003) 567-574
61. Petzke F., Gracely R.H., Khine A., and Clauw D.J. Pain sensitivity in patients with fibromyalgia (FM): expectancy effects on pain measurements [abstract]. Arthritis Rheum 42 (1999) S342
62. Petzke F., Khine A., Williams D., Groner K., Clauw D.J., and Gracely R.H. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 28 (2001) 2568-2569
63. Petzke F., Clauw D.J., Ambrose K., Khine A., and Gracely R.H. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 105 (2003) 403-413
64. Harris R.E., Gracely R.H., McLean S.A., et al. Comparison of clinical and evoked pain measures in fibromyalgia. J Pain 7 (2006) 521-527
65. Geisser M.E., Gracely R.H., Giesecke T., Petzke F.W., Williams D.A., and Clauw D.J. The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur J Pain 11 (2007) 202-207
66. 2 laser stimulation in subjects with fibromyalgia syndrome. Pain 58 (1994) 185-193
67. Kosek E., and Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 70 (1997) 41-51
68. Geisser M.E., Casey K.L., Brucksch C.B., Ribbens C.M., Appleton B.B., and Crofford L.J. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain 102 (2003) 243-250
69. Kosek E., Ekholm J., and Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 68 (1996) 375-383
70. Arroyo J.F., and Cohen M.L. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 20 (1993) 1925-1931
71. Gerster J.C., and Hadj-Djilani A. Hearing and vestibular abnormalities in primary fibrositis syndrome. J Rheumatol 11 (1984) 678-680
72. McDermid A.J., Rollman G.B., and McCain G.A. Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. Pain 66 (1996) 133-144
73. Lautenbacher S., and Rollman G.B. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 13 (1997) 189-196
74. Leffler A.S., Hansson P., and Kosek E. Somatosensory perception in a remote pain-free area and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from long-term trapezius myalgia. Eur J Pain 6 (2002) 149-159
75. Julien N., Goffaux P., Arsenault P., and Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114 (2005) 295-302
76. Baraniuk J.N., Whalen G., Cunningham J., and Clauw D.J. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 5 (2004) 48
77. Harris R.E., Clauw D.J., Scott D.J., McLean S.A., Gracely R.H., and Zubieta J.K. Decreased central μ-opioid receptor availability in fibromyalgia. J Neurosci 27 (2007) 10000-10006
78. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35 (1992) 550-556
79. Yunus M.B., Dailey J.W., Aldag J.C., Masi A.T., and Jobe P.C. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 19 (1992) 90-94
80. Arnold L.M., Keck P.E.J., and Welge J.A. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 41 (2000) 104-113
81. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
82. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119 (2005) 5-15
83. Russell I.J., Mease P.J., Smith T.R., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136 (2008) 432-444
84. Bennett R.M., Kamin M., Karim R., and Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114 (2003) 537-545
85. Gendreau R.M., Thorn M.D., Gendreau J.F., et al. The efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32 (2005) 1975-1985
86. Clauw D.J., Mease P., Palmer R.H., Gendreau R.M., and Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30 (2008) 1988-2004 [published correction appears in Clin Ther 2009;31:446]
87. Mease P.J., Clauw D.J., Gendreau R.M., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 36 (2009) 389-409 [published correction appears in J Rheumatol 2009;36:661]
88. Staud R., Vierck C.J., Cannon R.L., Mauderli A.P., and Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91 (2001) 165-175
89. Price D.D., Staud R., Robinson M.E., Mauderli A.P., Cannon R., and Vierck C.J. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 99 (2002) 49-59
90. Woolf C.J., and Thompson S.W. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain 44 (1991) 293-299
91. Woolf C.J. Windup and central sensitization are not equivalent. Pain 66 (1996) 105-108
92. Xu X.J., Dalsgaard C.J., and Wiesenfeld-Hallin Z. Spinal substance P and N-methyl-d-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex. Neuroscience 51 (1992) 641-648
93. Welin M., Bragee B., Nyberg F., and Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients [abstract]. J Musculoskel Pain 3 (1995) 4
94. Vaeroy H., Helle R., Førre O., Kåss E., and Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32 (1988) 21-26
95. Russell I.J., Orr M.D., Littman B., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37 (1994) 1593-1601
96. Bradley L.A., Alberts K.R., Alarcon G.S., et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) [abstract]. Arthritis Rheum 39 suppl (1996) S212
97. Sarchielli P., Di Filippo M., Nardi K., and Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 11 (2007) 343-351
98. Mountz J.M., Bradley L.A., Modell J.G., et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 38 (1995) 926-938
99. Kwiatek R., Barnden L., Tedman R., et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 43 (2000) 2823-2833
100. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 34 (2007) 130-134
101. Guedj E., Cammilleri S., Colavolpe C., et al. Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 34 (2007) 1274-1279
102. Guedj E., Cammilleri S., Colavolpe C., de L.C., Niboyet J., and Mundler O. Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT. Eur J Nucl Med Mol Imaging 34 (2007) 2115-2119
103. Guedj E., Cammilleri S., Niboyet J., et al. Clinical correlate of brain SPECT perfusion abnormalities in fibromyalgia. J Nucl Med 49 (2008) 1798-1803
104. Adiguzel O., Kaptanoglu E., Turgut B., and Nacitarhan V. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J 97 (2004) 651-655
105. Gracely R.H., Petzke F., Wolf J.M., and Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46 (2002) 1333-1343
106. Cook D.B., Lange G., Ciccone D.S., Liu W.C., Steffener J., and Natelson B.H. Functional imaging of pain in patients with primary fibromyalgia. J.Rheumatol 31 (2004) 364-378
107. Giesecke T., Gracely R.H., Williams D.A., Geisser M.E., Petzke F.W., and Clauw D.J. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 52 (2005) 1577-1584
108. Gracely R.H., Geisser M.E., Giesecke T., et al. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 127 (2004) 835-843
109. van West D., and Maes M. Neuroendocrine and immune aspects of fibromyalgia. BioDrugs 15 (2001) 521-531
110. Togo F., Natelson B.H., Adler G.K., et al. Plasma cytokine fluctuations over time in healthy controls and patients with fibromyalgia. Exp Biol Med (Maywood) 234 (2009) 232-240
111. Wang H., Moser M., Schiltenwolf M., and Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia-a prospective longitudinal study over 6 months. J Rheumatol 35 (2008) 1366-1370
112. Gur A., and Oktayoglu P. Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 12 (2008) 175-181
113. Rao S.G., and Bennett R.M. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol 17 (2003) 611-627
114. Abeles M., Solitar B.M., Pillinger M.H., and Abeles A.M. Update on fibromyalgia therapy. Am J Med 121 (2008) 555-561
115. Boissevain M.D., and McCain G.A. Toward an integrated understanding of fibromyalgia syndrome. IMedical and pathophysiological aspects. Pain 45 (1991) 227-238
116. Epstein S.A., Kay G.G., Clauw D.J., et al. Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics 40 (1999) 57-63
117. White K.P., Nielson W.R., Harth M., Ostbye T., and Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization?. A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 47 (2002) 260-265
118. Turk D.C., Okifuji A., Sinclair J.D., and Starz T.W. Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol 23 (1996) 1255-1262
119. Giesecke T., Williams D.A., Harris R.E., et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48 (2003) 2916-2922
120. Clauw D.J. The taxonomy of chronic pain: moving toward more mechanistic classifications. In: Wallace D.J., and Clauw D.J. (Eds). Fibromyalgia & Other Central Pain Syndromes (2005), Lippincott Williams & Wilkins, Philadelphia 9-16
121. Tan E.M., Feltkamp T.E., Smolen J.S., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40 (1997) 1601-1611
122. Pincus T. A pragmatic approach to cost-effective use of laboratory tests and imaging procedures in patients with musculoskeletal symptoms. Primary Care 20 (1993) 795-814
123. Jensen M.C., Brant-Zawadzki M.N., Obuchowski N., Modic M.T., Malkasian D., and Ross J.S. Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med 331 (1994) 69-73
124. Buskila D., and Sarzi-Puttini P. Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. Isr Med Assoc J 10 (2008) 77-78
125. Clauw D.J., and Katz P. The overlap between fibromyalgia and inflammatory rheumatic disease: when and why does it occur?. J Clin Rheumatol 1 (1995) 335-342
126. Goldenberg D.L., Burckhardt C., and Crofford L. Management of fibromyalgia syndrome. JAMA 292 (2004) 2388-2395
127. Norregaard J., Volkmann H., and Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61 (1995) 445-449
128. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 32 (2000) 305-316
129. Adelman L.C., Adelman J.U., Von Seggern R., and Mannix L.K. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 40 (2000) 572-580
130. Vaishnavi S.N., Nemeroff C.B., Plott S.J., Rao S.G., Kranzler J., and Owens M.J. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55 (2004) 320-322
131. Wiffen P., Collins S., McQuay H., Carroll D., Jadad A., and Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 3 (2000) CD001133
132. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
133. Arnold L.M., Russell I.J., Diri E.W., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9 (2008) 792-805
134. Mease P.J., Russell I.J., Arnold L.M., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35 (2008) 502-514
135. Redillas C., and Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 40 (2000) 83-102
136. Scharf M.B., Baumann M., and Berkowitz D.V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J.Rheumatol 30 (2003) 1070-1074
137. Russell I.J., Perkins A.T., and Michalek J.E. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 60 (2009) 299-309
138. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
139. Russell J., Michalek J.E., Xiao Y., Hynes W., Vertiz R., and Lawrence R. Therapy with a central alpha 2-adrenergic agonist (tizanidine) decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome [abstract]. Arthritis Rheum 46 (2002) S614
140. Williams D.A., Cary M.A., Glazer L.J., Rodriguez A.M., and Clauw D.J. Randomized controlled trial of CBT to improve functional status in fibromyalgia [abstract]. Arthritis Rheum 43 (2000) S210
141. Littlejohn G. The fibromyalgia syndrome: outcome is good with minimal intervention [letter]. BMJ 310 (1995) 1406
142. Macfarlane G.J., Thomas E., Papageorgiou A.C., Schollum J., Croft P.R., and Silman A.J. The natural history of chronic pain in the community: a better prognosis than in the clinic?. J Rheumatol 23 (1996) 1617-1620
143. Wolfe F., Anderson J., Harkness D., et al. Work and disability status of persons with fibromyalgia. J Rheumatol 24 (1997) 1171-1178